Skip to main content

Table 1 The association between DPYSL2 expression and prognosis in LUAD based on Kaplan–Meier plotter analysis

From: DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma

 

Overall survival (n = 719)

 

Progression-free survival (n = 641)

N

HR (95% CI)

p value

 

N

HR (95% CI)

p value

Gender

       

 Female

317

0.29 (0.19–0.45)

2.3e−09

 

235

1.99 (1.25–3.17)

0.0032

 Male

344

0.49 (0.34–0.68)

2.6e−05

 

226

2.96 (1.86–4.7)

1.5e−06

Stage

       

 1

370

0.34 (0.22–0.52)

2.1e−07

 

283

2.75 (1.65–4.61)

5.8e−05

 2

136

0.43 (0.26–0.72)

8e−04

 

103

1.38 (0.8–2.4)

0.25

 3

24

0.72 (0.25–2.07)

0.54

 

10

–

–

 4

4

–

–

 

0

–

–

T stage

       

 1

123

0.67 (0.36–1.24)

0.2

 

47

7.47 (0.89–62.42)

0.029

 2

105

0.77 (0.44–1.33)

0.34

 

93

1.59 (0.84–3.01)

0.15

 3

4

–

–

 

2

–

–

 4

0

–

–

 

0

–

–

N stage

       

 0

184

1.87 (1.14–3.05)

0.011

 

102

1.49 (0.68–3.25)

0.31

 1

44

1.18 (0.54–2.57)

0.68

 

38

3.16 (1.23–8.13)

0.012

 2

3

–

–

 

2

–

–

M stage

       

 0

231

1.56 (1.04–2.34)

0.028

 

142

2.17 (1.19–3.93)

0.0093

 1

1

–

–

 

0

–

–

Smoke

       

 Ever

246

2.03 (1.25–3.28)

0.0033

 

243

2.29(1.46–3.6)

0.00021

 Never

143

3.42 (1.35–8.62)

0.0057

 

143

3.1 (1.58–6.07)

5e−04

  1. HR hazard ratio, CI confidence interval. Values in bold indicate p < 0.05